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Merkel Cell Polyomavirus–Positive Merkel Cell
Carcinoma Cells Do Not Require Expression of
the Viral Small T Antigen
Sabrina Angermeyer1, Sonja Hesbacher1, Ju¨rgen C Becker2, David Schrama2 and Roland Houben1
Increasing evidence suggests that Merkel cell carcinoma (MCC) is caused by the Merkel cell polyomavirus (MCV).
The viral sequence encodes for two potential oncoproteins, i.e., the small T antigen (sT) and the large T antigen
(LT). Indeed, sT has recently been shown to bear transforming activity. Here, we confirm this observation by
demonstrating focus formation upon expression of MCV sT in NIH3T3 fibroblasts. On the other hand, however,
we provide evidence that established MCC cells do not require sT for growth and survival. Silencing of sT protein
expression by two different sT-specific short hairpin RNAs (shRNAs) leads to variable degrees of growth
retardation in MCV-positive MCC cell lines. However, these effects are not sT specific, as proliferation of MCV-
negative cell lines is similarly affected by these sT shRNAs. Furthermore, ectopic expression of shRNA-insensitive
sT does not revert the growth inhibition implicated by sT silencing. Finally, the unambiguous and specific growth
inhibition induced by means of an shRNA targeting both T antigens, can be completely rescued by ectopic
expression of LT alone, thus demonstrating a dispensable role of sT. Altogether, our results indicate that MCV LT
is more relevant in maintaining the proliferation and survival of established MCC cell lines.
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INTRODUCTION
Merkel cell carcinoma (MCC) is the most aggressive skin
cancer with one-third of the affected patients dying from their
disease (Becker, 2010). MCC is a very rare malignancy,
although its incidence is rising (Hodgson, 2005). Risk factors
for developing MCC are immunosuppression, UV exposure,
and old age (Becker et al., 2009b). The molecular pathogenesis
of MCC has been elucidated by the discovery of a new polyo-
mavirus, termed Merkel cell polyomavirus (MCV), integrated
into the genome of most MCCs (Feng et al., 2008). Many
groups have confirmed the presence of MCV in about 80% of
MCC tumors (Kassem et al., 2008; Becker et al., 2009a; Garneski
et al., 2009), but this might actually be an underestimation as
sensitivity of MCV detection is higher when fresh or frozen
samples (Martel-Jantin et al., 2012) or improved immunohisto-
chemistry and PCR methods are used (Rodig et al., 2012).
MCV, like other polyomaviruses, encodes the T antigens
(TAs), i.e., the small and the large T antigen (sT and LT; Shuda
et al., 2008, 2009, 2011). These are derived by alternative
splicing from a common gene locus; the first 78 N-terminal
amino acids are shared, whereas the C terminus is different. In
contrast to wild-type LT, most of the MCC-associated LTs are
truncated deleting a part of LT necessary for virus replication.
This is caused either by integration break points within the LT
sequence or by stop codon mutations (Shuda et al., 2008;
Schmitt et al., 2012). The retinoblastoma protein-binding motif,
however, is generally preserved in MCC suggesting an essential
function of the interaction of LT with the cell cycle regulator
protein retinoblastoma protein for MCC tumorigenesis.
Knockdown of TA expression using short hairpin RNAs
(shRNAs) targeting both TAs induces cell cycle arrest and
apoptosis of MCVþ MCC cell lines in vitro and regression of
established xenograft tumors (Houben et al., 2010, 2012).
Consequently, TAs are regarded as attractive therapeutic
targets to treat MCC. In order to develop such a therapeutic
approach, the extent to which sT and LT contribute to the
oncogenic phenotype of MCVþ MCC cells has to be establi-
shed. Notably, the TA shRNA-induced anti-proliferative
effects can be rescued by ectopic expression of shRNA
insensitive TA. This rescue, however, is abrogated by a point
mutation in LT interfering with its ability to bind to the
retinoblastoma protein (Houben et al., 2012). Moreover,
specific knockdown of LT alone inhibits proliferation of
MCVþ MCC, which again can be rescued by re-expression
of LT (Houben et al., 2012).
Here, we scrutinize to which extent MCVþ MCC cell lines
are addicted to MCV sT for continuous proliferation. To this
end, silencing of sT protein expression by sT-specific shRNAs
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led to variable degrees of growth inhibition of both MCV
and MCVþ MCC cell lines. Furthermore, ectopic expression
of shRNA-insensitive sT did not revert the growth inhibition
induced by sT silencing, whereas ectopic expression of only
LT could rescue the TA knockdown phenotype.
RESULTS AND DISCUSSION
Shuda et al. (2011) recently reported that MCV encoded sT
bears transforming activity. Moreover, using the MCVþ MCC
cell line, MKL-1, they demonstrated that shRNA knockdown
of sT impeded cellular metabolic activity. Indeed, as measured
by Wst-1 assay, the inhibiting effect was as strong as upon
knockdown of both TAs (Shuda et al., 2011). However, in
contrast to TA knockdown no increased cell death and only
moderate cell cycle effects were observed upon sT silencing;
thus the modus operandi of the inhibitory effects of sT
knockdown were left in uncertainty. Prompted by this
report, we scrutinized the dependence of MCVþ MCC cells
on sT expression in more detail. For this purpose, we used one
established TA-specific shRNA targeting both LT and sT and
two different new sT-specific shRNAs; the latter is important as
shRNAs frequently exhibit off-target effects (Jackson et al.,
2006).
All three shRNAs were effective in knocking down sT
expression, whereas only the TA-specific shRNA reduced LT
expression (Figures 1a and 2). As the used lentiviral shRNA
vectors also encode green fluorescent protein (GFP), the
shRNA induced changes in the proliferation of three MCVþ
and two MCV cell lines could be pinpointed in mixed
cultures with unmarked control cells. Although the TA-specific
shRNA uniformly inhibited the growth of all three MCVþ
cells, the effect of sT-specific shRNAs was very variable.
Furthermore, sT-specific shRNAs also exerted some growth
inhibitory effects on one of the MCV cell lines (Figure 1b
and c). These observations already suggested off-target effects
of the sT-specific shRNAs. To formally distinguish between
specific and off-target effects, we performed rescue experi-
ments by stably expressing sT rendered insensitive to either of
the sT-specific shRNA in MCVþ MCC cell lines (Figure 2).
Notably, virtually no rescue of the shRNA-induced growth
inhibition was observed.
The interpretation of these results, however, is complicated
by the fact that due to the low expression levels of sT (Houben
et al., 2010; Shuda et al., 2011), we did not succeed to
measure endogenous sT protein: even when using three
different antibodies targeting either an epitope in exon 1
common to sT and LT (2T2, CM8E6) or an sT-specific epitope
(CM5E1) no sT could be detected by immunoblot analyzing
lysates from WaGa (Figure 3) or any other MCVþ MCC cell
line (data not shown). As control, sT overexpressed in 293 T
cells was readily detectable (Figure 3). Anyhow, such a low sT
expression per se argues against an essential role of sT for the
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Figure 1. Variable response of Merkel cell polyomavirus (MCV)-positive Merkel cell carcinoma (MCC) cell lines to two small T antigen (sT)-specific short
hairpin RNAs (shRNAs). (a) HEK 293T cells were co-transfected with an expression construct for V5-tagged MCV sT and the indicated shRNA constructs
targeting either T antigen (TA), large T antigen (LT), or sT (two different shRNAs: sT1 and sT2). A scrambled shRNA (Scr) was used as control. Total cell lysates
harvested after 2 days of incubation were subjected to immunoblot analysis using a V5 antibody to visualize sT expression. WaGa cells infected with the same
shRNA constructs were analyzed on day 5 after infection for expression of MCV LT. (b and c) The indicated MCV-negative (b) and MCV-positive (c) cell lines were
infected with the lentiviral shRNA constructs also coding for GFP and were then mixed with uninfected parental cells. Ratios of fluorescent/non-fluorescent
cells were measured over time. Mean values (± SD) of 8 (WaGa), 3 (MKL-2), 6 (MKL-1 and MCC13), or 7 (Jurkat) independent experiments are depicted.
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MCC cells. Nevertheless, to redress the inability to monitor
endogenous sT protein expression additional rescue experi-
ment were performed. We have previously demonstrated that
the used TA shRNA effectively reduces LT and sT levels
(Figures 1a and 4a; Houben et al., 2010). Notably, this TA
knockdown-induced growth inhibition is completely rescued
by expression of a TA shRNA insensitive LT (Figure 4). Indeed,
the rescue by expression of shRNA-insensitive LT is as efficient
as the rescue by an shRNA-insensitive TA (Figure 4). It should
further be noted that the rescue capacity of a shRNA
insensitive TA expression vector is completely abrogated by
a mutation affecting only LT (Houben et al., 2012). The above-
described results suggest that MCVþ MCC cells do not
essentially require sT expression for proliferation and
survival. It should be noted, however, that in contrast to the
low expression levels of sT in MCC cell lines in vitro and in
MCC tissues in situ, sT is more frequently detected in MCC
tissues by immunohistochemistry than LT (Shuda et al., 2011);
this notion argues for an important role of sT in tumor
maintenance. Then again, a recent publication using a new
LT antibody demonstrates LT expression in virtually all MCC
samples by immunohistochemistry (Rodig et al., 2012).
Our observations suggest that LT is more relevant for
proliferation and survival of the MCVþ MCC cells than sT,
as the strict oncogene addiction is only apparent for LT
(Figures 1, 2 and 4). Still, MCV sT bears a higher transforming
capacity on fibroblasts than LT (Shuda et al., 2011) implying
that MCV sT might be the dominant oncogene in MCC
tumorigenesis. This is not necessarily a contradiction as it is
conceivable that sT is more involved in the initial oncogenic
transformation, whereas LT is more important for the
maintenance of established MCC cells. To confirm this split
in importance of the two TAs in these two processes, we
reevaluated the transforming capability of the MCV TAs by
comparison to established oncogenic proteins such as the
SV40 TAs and BRAFV600E (Ali and DeCaprio, 2001; Hahn
et al., 2002; Houben et al., 2004). To this end, NIH3T3
fibroblasts were infected with high-titer lentiviral expression
vectors leading to stable integration of the expression
constructs in at least 30% of the cells (data not shown).
Consistent with the results of Shuda et al., we observed
induction of focus formation only by the MCV sT expression
construct, whereas the vector carrying an MCC-derived
truncated MCV LT complementary DNA (cDNA) did not
induce foci (Figure 5 a and b). Focus formation in MCV sT-
expressing fibroblasts, however, was very weak compared
with SV40 early region or BRAFV600E. Actually, although for
MCV sT construct only small foci just started to form 25 days
after infection, for the BRAFV600E or SV40 early region
constructs the complete plate was covered with morphologi-
cally transformed cells, which had lost contact inhibition
(Figure 5b). The difficulty to recapitulate transforming capacity
of the MCV TAs in vitro is not unique to MCV as, e.g., Kaposi’s
sarcoma-associated herpes virus does not induce full transfor-
mation when analyzed in vitro (Mesri et al., 2010). Such an
effect may be due to the lack of microenvironmental co-
factors in the cell culture system (Madkan et al., 2007;
Boccardo et al., 2010). Alternatively, the inability of MCV
LT to induce focus formation may be attributable to the fact
that fibroblasts are not the ideal target cells. To date, only
MCC has been convincingly demonstrated to be caused by
MCV although MCV is widespread (Pastrana et al., 2009),
can be detected in many different organs (Matsushita et al.,
2012), and seems to have a broad entry tropism (Schowalter
et al., 2012). These observations and the fact that MCC is a
very rare disease suggest that only a limited number of cell
types can be transformed by MCV; thus, only in this respective
cell type the genuine transforming ability of the MCV TAs can
be established.
In summary, the data presented here confirm transforming
activity of MCV sT in mouse fibroblasts, but suggest that
established MCC cells do not essentially depend on sT
expression. In contrast, MCV encoded LT, which cannot
transform fibroblasts, is strictly required for growth and
survival of MCVþ MCC cells. Thus, MCV LT appears to be
the more suitable target for therapeutic approaches to treat
patients with clinically evident MCC.
MATERIALS AND METHODS
Cell culture
The MCV-positive MCC cell lines WaGa (Houben et al., 2010), MKL-1
(Rosen et al., 1987), and MKL-2 (Van Gele et al., 2002) as well as
the MCV-negative MCC cells MCC13 (Leonard et al., 1995) and the
T-cell lymphoma cell line Jurkat (Gillis and Watson, 1980) were used.
All cell lines were grown in RPMI 1640 supplemented with 10% fetal
calf serum, 100 U ml 1 penicillin, and 0.1 mg ml 1 streptomycin.
MKL-1 and MKL-2, which grow as spheroids, were dissociated with
Trypsin-EDTA solution before lentiviral infections, cell counting, or
flow cytometric analysis. Cell lines stably expressing shRNA-
insensitive LT or sT were raised by infection of the cells with
retroviral expression constructs (pIH) containing a hygromycin-
resistance gene and the respective cDNA. Hygromycin-resistant
cells were selected by a 3-week culture in the presence of
100mg ml 1 hygromycin B.
shRNA constructs
The lentiviral shRNA vector KH1, which drives constitutive co-
expression of an shRNA and GFP (Verhaegen et al., 2006), was
used to achieve knockdown of sT or of both MCV TAs. For the latter,
an shRNA sequence (sense strand 50-ATCCACAAGCTCAGAAG
TGACTTCTCTATTCAAGAGATAGAGAAGTCACTTCTGAGCTTGTG
GATTTTTTT-30) designed to target the nucleotides 391–419 (acces-
sion number: EU375803) present in all T-antigen messenger RNAs
(see Figure 1) was used. To specifically target sT either the shRNA
sequence sT1 (sense strand 50-GCTTAAGCAACTTAGAGATTCTAT
CAAGAGTAGAATCTCTAAGTTGCTTAAGCTTTTTT-30) correspond-
ing to the nucleotides 525–547 (accession number: EU375803) or
sT2 (sense strand 50-GGAAGAATATGGAACTTTATCAAGAGTA
AAGTTCCATATTCTTCCTTTTTT-30) corresponding to the nucleotides
450–468 (accession number: EU375803), respectively, were cloned
into the KH1 vector. As control, a scrambled KH1 construct targeting
neither human nor MCV transcripts was used.
TA expression constructs
For generation of MCC cell lines stably expressing ectopic shRNA-
insensitive sT, LT, or TA, the respective cDNAs were cloned into the
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retroviral vector pIH containing a hygromycin-resistance gene
(Houben et al., 2012). The TA gene derived from MCC339 (acce-
ssion number EU375804) inserted in the pcDNA6 vector served as
template for PCR amplification of an sT cDNA. For cloning of LT, we
used cDNA generated from messenger RNA derived from 293T cells
transfected with a MCC339 derived TA gene construct carrying a stop
codon mutation (C1461T according to accession number EU375803)
truncating the protein after amino acid 278. sT primers to generate the
appropriate restriction sites for cloning into pIH were designed to add
a C-terminal V5 tag to the sT cDNA.
To render ectopically expressed mRNAs insensitive to a specific
shRNA silent mutations in the respective shRNA target sequence
were introduced using the quick change mutagenesis kit (Stratagene,
La Jolla, CA). The TAs shRNA target sequence was modified
by changing the sequence from ATCCACAAGCTCAGAAGTG
ACTTCTCTAT to ATTCATAAACTCAGGAGCGACTTCTCGAT. The
sT1 and the sT2 shRNA target sequences were modified by changing
the sequence from 50-GCTTAAGCAACTTAGAGATTCTA-30 to
50-GCTCAAACAGCTTAGGGACTCAA-30 and from 50-GGAAG
AATATGGAACTTTA-30 to 50-GGAGGAGTACGGTACCCTT-30,
respectively.
For the transformation assays, the respective inserts were
sub-cloned into the lentiviral expression vector pCDH coding for
GFP as well (System Biosciences, Mountain View, CA).
Retro- and lentiviral infection
Retro- and lentivirus containing supernatants were generated
by transient transfection of HEK293T cells using two (pHIT60
and pHIT456) and three (pRSV rev, pHCMV-G and pMDLg/pRRE)
helper constructs, respectively. Two days following transfection,
virus supernatants were harvested. Following filtration through
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Figure 2. No rescue of small T antigen (sT) short hairpin RNA (shRNA)-induced growth inhibition by ectopic expression of Merkel cell polyomavirus (MCV) sT.
MKL-1 and WaGa cells were stably transduced with empty vector or with expression constructs for V5-tagged MCV sT. The sT messenger RNAs encoded by these
constructs were rendered insensitive to either sT1 shRNA or sT2 shRNA by introducing six silent mutations in the respective shRNA target sequences.
Subsequently, the cells carrying these constructs were infected with the indicated lentiviral shRNA expression constructs coding also for GFP. Left side: Expression
of ectopic sT (anti-V5 antibody), MCV large T antigen (LT; antibody: CM2B4), and tubulin was measured by immunoblot in cell lysates harvested 5 days after
shRNA infection. Right side: The ratios of a mixed population of green fluorescent shRNA-infected cells with uninfected, non-fluorescent cells were determined
over time. Mean values (± SD) of three independent experiments are depicted.
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0.45-mm pore size filters and supplementation with 1mg ml 1
polybrene, the virus containing supernatant was added to the
target cells. Following overnight incubation, cells were washed twice
with medium. As KH1 also encodes GFP the infection rate could
be determined by flow cytometry (FACSCanto; BD Biosciences,
Heidelberg, Germany).
GFP assay
GFP expression by KH1-infected cells was used to compare the
behavior of infected and uninfected cells: infected cells were mixed
with approximately 20% of uninfected cells. Changes in the
frequency of GFP-positive cells in this mixture were determined by
flow cytometry over time.
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Figure 4. T antigen (TA) knockdown is rescued by re-expression of large T antigen (LT). The indicated Merkel cell carcinoma (MCC) cell lines were stably
transduced with empty vector or with expression constructs containing either a truncated Merkel cell polyomavirus (MCV) LT complementary DNA (stop codon
279) or MCV TA gene coding for sT and LTstop279. Owing to introduction of six silent mutations in the short hairpin RNA (shRNA) target sequence, the messenger
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independent experiments are depicted. Growth of the corresponding Scr shRNA controls was not affected (data not shown).
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Figure 5. Weak transforming activity of Merkel cell polyomavirus (MCV) small T antigen (sT) but not truncated MCV large T antigen (LT) in NIH3T3
cells. NIH3T3 cells were infected with lentiviral expression constructs for the indicated proteins. The MCV LT complementary DNA carried a stop codon mutation
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Immunoblotting
Cells were lysed in 0.6% SDS, 1 mM EDTA, 10 mM Tris-HCl (pH 8.0),
2 mM NaF, and 2 mM NaVO3 supplemented with a protease inhibitor
cocktail (Roche Diagnostics, Basel, Switzerland). Samples were
resolved by SDS-PAGE and transferred to nitrocellulose membranes.
Following 1 h blocking with phosphate-buffered saline (PBS) contain-
ing 0.05% Tween-20 and 5% powdered skim milk, membranes were
incubated overnight with primary antibody, washed three times with
PBS with 0.05% Tween-20 (PBS/Tween), and then incubated with a
peroxidase-coupled secondary antibody. Following three washes with
PBS/Tween, bands were detected using a chemiluminescence detec-
tion kit (Thermo Fisher Scientific, Rockford, IL). The antibodies used
in this study were directed against MCV LT (CM2B4; Santa Cruz
Biotechnology, Santa Cruz, CA), MCV sT (CM5E1; gift from Patrick
Moore), MCV TA (2T2; gift from Christopher Buck, and CM8E6;
gift from Patrick Moore), the V5 tag (Abcam, Cambridge, MA),
or b-tubulin (Sigma-Aldrich, Taufkirchen, Germany).
Transformation assay
A total of 2 105 NIH3T3 cells were seeded in 6-well plates and TA
expression constructs were stably introduced by infection with
lentiviral supernatants generated in HEK293T cells. One day after
infection, cells were transferred to T75 flasks and on day four,
infection rates determined by flow cytometry analysis varied between
30 and 70%. On day 25 after infection, focus formation was
monitored by microscopy and crystal violet staining.
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